New combo therapy shows promise for advanced nose cancer
NCT ID NCT03734809
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a treatment plan for people with stage IVA nasopharyngeal cancer (a type of nose and throat cancer). Participants receive a combination of the immunotherapy drug pembrolizumab and chemotherapy before and during radiation, followed by maintenance pembrolizumab for up to a year. The goal is to see if this approach improves how long the cancer stays away. The study enrolled 43 adults and is no longer recruiting new participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IVA NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Clinical Oncology, Prince of Wales Hospital
Hong Kong, Hong Kong
-
National Cancer Centre of Singapore
Singapore, Singapore